LifeStance Health Group (NASDAQ:LFST) Trading 4.5% Higher - Here's Why

Key Points

• LifeStance Health Group shares rose 4.5% to $5.40, despite a 40% decline in trading volume compared to average sessions.
• Analysts have issued predominantly positive ratings, with UBS raising its price target to $9.00 and a consensus rating of "Moderate Buy" reflected among analysts.
• The company's latest financial results showed a revenue increase of 10.6% year-over-year, with an EPS of ($0.01), which is better than analysts' expectations.

LifeStance Health Group, Inc. (NASDAQ:LFST - Get Free Report) shares traded up 4.5% on Thursday . The stock traded as high as $5.39 and last traded at $5.40. 1,180,048 shares were traded during trading, a decline of 40% from the average session volume of 1,960,861 shares. The stock had previously closed at $5.17.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the stock. UBS Group increased their price objective on shares of LifeStance Health Group from $8.50 to $9.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. BTIG Research assumed coverage on shares of LifeStance Health Group in a research note on Friday, July 25th. They set a "buy" rating and a $8.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of LifeStance Health Group from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $8.50.

LifeStance Health Group Stock Up 5.7%

The firm's 50 day simple moving average is $4.70 and its 200 day simple moving average is $6.13. The company has a market cap of $2.13 billion, a price-to-earnings ratio of -109.10 and a beta of 1.13. The company has a quick ratio of 1.47, a current ratio of 1.48 and a debt-to-equity ratio of 0.19.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. The company had revenue of $345.31 million for the quarter, compared to analyst estimates of $345.05 million. LifeStance Health Group had a negative net margin of 1.23% and a negative return on equity of 1.11%. LifeStance Health Group's revenue was up 10.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.06) earnings per share. Sell-side analysts anticipate that LifeStance Health Group, Inc. will post -0.18 EPS for the current fiscal year.

Insider Activity

In other news, insider Ujjwal Ramtekkar sold 16,000 shares of the stock in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $5.94, for a total value of $95,040.00. Following the completion of the transaction, the insider directly owned 113,435 shares in the company, valued at $673,803.90. This trade represents a 12.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 3.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LFST. Parcion Private Wealth LLC bought a new position in shares of LifeStance Health Group in the first quarter valued at approximately $15,670,000. Dimensional Fund Advisors LP boosted its holdings in LifeStance Health Group by 87.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,524,529 shares of the company's stock worth $25,977,000 after buying an additional 1,643,390 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in LifeStance Health Group during the first quarter worth approximately $7,932,000. Qube Research & Technologies Ltd boosted its holdings in LifeStance Health Group by 90.5% during the second quarter. Qube Research & Technologies Ltd now owns 2,455,027 shares of the company's stock worth $12,692,000 after buying an additional 1,166,045 shares in the last quarter. Finally, Nuveen LLC bought a new stake in LifeStance Health Group during the first quarter worth approximately $6,928,000. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.